Macrogen USA, one of the leading providers of next-generation sequencing services, has been announced as a participating provider in precisionFDA. The precisionFDA web platform is part of President Obama’s vision with his Precision Medical Initiative announced last year. The administration’s goal is to move away from a “one-size-fits-all” approach to medicine and move towards a […]
The emergence and growth of whole genome sequencing technologies, and the resulting immense database generated, requires that scientists and medical professionals learn more about the powerful tools available to them. These tools give scientists the ability to interpret and apply the information and are becoming increasingly available. Genomic technologies have bolstered the power of personalized […]
Introduction The newest sequencing technologies are providing new insights into disease etiology, individual susceptibilities, keys to drug discovery, and more. However, there are many questions and challenges regarding how to understand the meaning and applicability of the newfound wealth of data. As new data is generated at record rates, scientists are working diligently on the […]
Macrogen recently partnered with Edico Genome to reinforce its Bio-IT infrastructure with new DRAGEN processors. By deploying several DRAGEN Bio-IT Processors, which are designed and manufactured by Edico Genome, Macrogen will be able to provide faster processing and analysis of high-throughput NGS data. Accurate DNA sequencing and genomic analysis is reliant on advanced technology. To […]
The Genome Asia 100K Initiative announcement made big waves earlier this year as it is the first significant pan-Asian endeavor with the goal of creating a comprehensive genomic database. The initiative is similar to the 100K Genome Project in the United Kingdom and the US Precision Medicine Initiative. The Genome Asia 100K initiative is led […]
Psomagen, Inc. (previously Macrogen Corp.), established in 2004, offers “total genomic solutions” for both clinical and research purposes, mainly focusing on end-to-end sequencing services. The company will expand its services to include personal DNA tests.